Angiotensin-(1–7) in kidney disease: a review of the controversies
The DOI matches its Crossref record.
Abstract
Ang-(1–7) [angiotensin-(1–7)] is a biologically active heptapeptide component of the RAS (renin–angiotensin system), and is generated in the kidney at relatively high levels, via enzymatic pathways that include ACE2 (angiotensin-converting enzyme 2). The biological effects of Ang-(1–7) in the kidney are primarily mediated by interaction with the G-protein-coupled receptor Mas. However, other complex effects have been described that may involve receptor–receptor interactions with AT1 (angiotensin II type 1) or AT2 (angiotensin II type 2) receptors, as well as nuclear receptor binding. In the renal vasculature, Ang-(1–7) has vasodilatory properties and it opposes growth-stimulatory signalling in tubular epithelial cells. In several kidney diseases, including hypertensive and diabetic nephropathy, glomerulonephritis, tubulointerstitial fibrosis, pre-eclampsia and acute kidney injury, a growing body of evidence supports a role for endogenous or exogenous Ang-(1–7) as an antagonist of signalling mediated by AT1 receptors and thereby as a protector against nephron injury. In certain experimental conditions, Ang-(1–7) appears to paradoxically exacerbate renal injury, suggesting that dose or route of administration, state of activation of the local RAS, cell-specific signalling or non-Mas receptor-mediated pathways may contribute to the deleterious responses. Although Ang-(1–7) has promise as a potential therapeutic agent in humans with kidney disease, further studies are required to delineate its signalling mechanisms in the kidney under physiological and pathophysiological conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
The ACE2/angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)
Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2016 · Cited by 1,144
ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis
Simões e Silva, A., Silveira, K., Ferreira, A., & Teixeira, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12159 · Cited by 542
Santos, R. A. S., Ferreira, A. J., Verano-Braga, T., & Bader, M. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0341 · Cited by 523
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Metadata
- Authors
- Zimmerman, D., & Burns, K. D.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2012-05-29
- Volume
- 123
- Issue
- 6
- Pages
- 333-346
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2018119516
- Cited by
- 111
- References
- 0
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiotensin-(1–7) in kidney disease: a review of the controversies. https://app.cochat.ai/papers/10.1042/cs20120111
- The paper
- Zimmerman, D., & Burns, K. D. (2012). Angiotensin-(1–7) in kidney disease: a review of the controversies. Clinical Science. https://doi.org/10.1042/cs20120111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.